3M Pharmaceuticals (NYSE:MMM) 3M is a $21 billion diversified technology company with leading positions in consumer and office; display and graphics; electronics and telecommunications; health care; industrial and transportation; safety, security and protection services and other businesses.
Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, are manufactured in the AastromReplicell® System, an industry-unique automated cell production system. Aastrom's TRC cell products are in clinical trials for the following therapeutic indications: severe bone fractures (U.S.: Phase I/II - multi-center; EU: Phase I/II - multi-center), ischemic vascular disease (EU: Phase I/II), jaw bone reconstruction (EU: proof of concept) and spine fusion (U.S.: Phase I/II - single-center). The Company has recently reported positive clinical trial results for its TRCs demonstrating both the clinical safety and ability of TRCs to induce healthy new tissue growth.
ABAXIS, Inc. (Nasdaq: ABAX) ABAXIS develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform 23 different assays and 8 different profiles on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.
ABBOTT LABORATORIES (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 60,000 people and markets its products in more than 130 countries.
Abgenix (NasdaqNM:ABGX) Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com .
ABIOMED INC (NasdaqNM:ABMD) Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The Company's AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.
ABLE LABORATORIES (Other OTC: ABLSQ.PK) Able Laboratories, Inc. is a developer and manufacturer of generic pharmaceutical products in tablet, capsule, liquid and suppository dosage forms. In May 2005, Able suspended manufacturing and distribution of its entire product line. The company currently is not generating income or revenue, because of its suspension of manufacturing operations and product recalls. The company has filed a petition to reorganize under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of New Jersey, Trenton Division on July 18, 2005.
ACAMBIS PLC ADS (NasdaqNM:ACAM) Acambis is a biotechnology company discovering, developing and manufacturing novel vaccines to prevent and treat infectious diseases. We are based in Cambridge, UK and Cambridge, Massachusetts, USA.
Aclara Biosciences Inc (NASDAQ NM) Develop, manufacture and supply of innovative biology assays as part of the eTag TM Assay System. The System comprises of reagent kits, software and services that simplify and automate various aspects of drug development, pre-clinical testing and clinical assessment. The Company's eTag assays represent a universal platform for the analysis of genes, proteins and cellular pathways and can be analyzed using existing capillary electrophoresis instrumentation systems. The eTag assays applicable in the development of the new paradigm of molecular medicine for patient-specific therapeutic treatments based on individual genotypes and phenotypes derived from predictive biomarkers. The Company develops and commercializes these high content assays initially in the target areas of oncology and toxicogenomics.
Acrongenomics, Inc. (OTCBB: AGNM) is a Research & Development nanobiotechnology company pioneering the development of uniquely advanced nanomolecular diagnostics for the Life Sciences Industry. The Company seeks to establish its proprietary nanotechnology platform as a standard in Molecular In Vitro Diagnostics. Acrongenomics is dedicated to transforming scientific concepts into reality, as it has successfully applied Nanotechnology inspirations into next-generation Biotechnology applications.
